Press releases

Today, Boston Scientific (NYSE: BSX) announced positive data for two devices within the peripheral drug-eluting product portfolio during separate late-breaking clinical trial presentations at...

Boston Scientific Corporation (the "Company") (NYSE:BSX) today announced that, pursuant to the previously announced cash tender offer (the "Tender Offer") for up to $1.0 billion aggregate...

"Our third quarter results reflect accelerated growth,” said Mike Mahoney, chairman and CEO, Boston Scientific. Read the October 23, 2019 announcement.

Boston Scientific announced the commencement of a cash tender offer for up to $1.0 billion of outstanding senior notes.

Study of abbreviated antiplatelet therapy for patients at high risk for bleeding after percutaneous coronary intervention.

Notably, key data from the EVOLVE Short DAPT study of the SYNERGY stent will be featured during a late-breaking science session.

System is designed to treat Parkinson's Disease symptoms by delivering precisely targeted electrical stimulation.

BTG acquisition brings best-in-class minimally-invasive technologies for procedures targeting cancer and vascular diseases to Boston Scientific.

"The consistent execution of our global teams continues to help us grow the majority of our businesses faster than the market,” said Mike Mahoney.

Momentum across business units and regions targeted to deliver top tier revenue growth and double-digit adjusted earnings per share growth with strong adjusted free cash flow.

Vertiflex acquisition adds the only FDA-approved, commercially available, minimally invasive interspinous spacer to Boston Scientific’s chronic pain portfolio.

WATCHMAN device findings could expand number of non-valvular atrial fibrillation (AFib) patients who can receive alternative treatment to lifelong use of blood thinners.

New clinical trial data further support use of Boston Scientific’s EMBLEM S-ICD System as first-line therapy for majority of ICD patients.

Acquisition of lumbar spinal stenosis treatment to expand portfolio of interventional pain therapies.

New stent system now available for treating patients with deep venous blockages.

"With our strong pipeline and category leadership strategy, we are confident in our top tier 2019 outlook,” said CEO Mike Mahoney. Read the April 2019 release.

Transcatheter aortic valve replacement technology for patients with severe aortic stenosis designed to minimize paravalvular leakage, offer controlled delivery and repositionability post deployment.

New data showcases safety & efficacy of recently acquired RF balloon-based, single-shot ablation technology when treating patients with AFib.

Company begins limited market release in Europe for next generation WATCHMAN device, intended to reduce the risk of stroke in people with non-valvular AFib.

Solutions for nutrition support and early detection of respiratory issues win and place at Connected Patient Challenge competition focused on chronic conditions.

Boston Scientific Corporation (NYSE: BSX) announced its completed public offering of senior notes.

Boston Scientific Corporation (NYSE: BSX) announced the pricing of a public offering of senior notes.

"Meaningful innovation and focused execution helped us deliver strong financial results in 2018," said CEO Mike Mahoney.

Rezūm patients experienced significant and sustained improvement in benign prostatic hyperplasia (BPH) symptoms and quality of life.

Advanced systems offer customizable therapy to treat Parkinson's symptoms.

Boston Scientific venous stent met VIRTUS trial primary effectiveness and safety endpoints in re-establishing blood flow.

Boston Scientific will webcast its conference call with financial results and business highlights for Q4 2018 and the full 2018 year.

Acquisition will expand structural heart portfolio to include transcatheter mitral annuloplasty repair system

Delaware court rules Edwards Lifesciences Infringes Boston Scientific patent

Transaction would expand Boston Scientific peripheral interventions portfolio with minimally invasive treatments for cancers and vascular conditions

"Through internal research and tuck-in acquisitions, we continue to bring meaningful innovations to market,” said CEO Mike Mahoney.

Court rules Edwards Lifesciences’ next-generation valve infringes Boston Scientific patent and grants right to enjoin sales in Germany.

The acquisition brings SpaceOAR, which decreases exposure to rectal radiation during prostate cancer radiotherapy, into the Boston Scientific portfolio.

Data support minimally invasive single-incision mesh procedure as a durable, safe and effective treatment for stress urinary incontinence.

Eluvia is the first peripheral vascular interventional technology approved in U.S. to offer a sustained release of a drug to treat peripheral artery disease.

First head-to-head trial assesses effectiveness of sustained drug release in interventional treatment for patients with blockages in femoropopliteal arteries.

New data at World Congress of Endourology demonstrate the Lithovue Empower device for kidney stone retrieval improves the OR experience.

Key data will include results from IMPERIAL trial evaluating ELUVIA drug-eluting stent and from REPRISE III study evaluating LOTUS Aortic Valve System.

Acquisition expands Boston Scientific portfolio of men's health in-office procedures with SpaceOAR, an adjunctive therapy for prostate cancer patients.

Acquisition will bolster Boston Scientific peripheral interventions portfolio with a treatment for venous obstructive disease

Boston Scientific acquisition adds the Sentinel® Cerebral Protection System, the only device cleared to protect patients against stroke risk in TAVR procedures.

"We're excited about the ways our differentiated pipeline will continue to drive our growth," said CEO Mike Mahoney.

Company does not endorse TRC's unsolicited mini-tender offer and recommends stockholders take no action.

Acquisition will add FDA-cleared Sentinel® Cerebral Embolic Protection System to expand Boston Scientific structural heart offerings.

Acquisition to expand Boston Scientific atrial fibrillation (Afib) ablation therapy offerings with innovative cryoballoon platform.

Data highlight the successful reduction of inappropriate shocks using the sensing filter in patients implanted with the EMBLEM™ S-ICD System.

Acquisition adds Rezūm®, a therapy for patients with symptomatic benign prostatic hyperplasia (BPH).

"Our consistently strong performance reflects our team's ongoing dedication,” said CEO Mike Mahoney.

Data demonstrated safety and effectiveness of VERCISE™ DBS System for controlling Parkinson’s symptoms.

European patent office revokes Edwards Lifesciences '550 patent.